Panobinostat
An HDAC inhibitor for relapsed myeloma approved in 2015 and withdrawn in 2021 after its confirmatory trial was never completed.
PANORAMA-1: PFS 12 vs 8.1 months with bortezomib-dexamethasone, at the cost of severe diarrhoea and cardiac events; accelerated approval 2015 restricted to patients after ≥2 regimens. Secura Bio withdrew the US approval in 2021.
Approvals
| Region | Year | Indication |
|---|---|---|
| US | 2015 | Multiple myeloma after ≥2 regimens including bortezomib and an IMiD — Withdrawn 2021 |
| EU | 2015 | Relapsed/refractory multiple myeloma |
Trials
topRecruiting now (live from ClinicalTrials.gov)
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Latest papers
topQuery for this drug: (TITLE:"Panobinostat" OR ABSTRACT:"Panobinostat" OR TITLE:"Farydak" OR ABSTRACT:"Farydak") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Panobinostat, not a curated reading list.
Pages like this
not linked directly; found by shared links- ProductBelinostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductRomidepsin
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductElotuzumab
Shares Multiple myeloma and the tag gap-fill.
- ProductTretinoin (all-trans retinoic acid, ATRA)
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductArsenic trioxide
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductIxazomib
Shares Multiple myeloma and the tag gap-fill.
- ProductTazemetostat
Shares Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET) and the tag gap-fill.
- ProductPomalidomide
Shares Multiple myeloma and the tag gap-fill.